Company Analysis

Spero Therapeutics, Inc. (SPRO)

Nasdaq: SPRO · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2017
Grade6.1
◀ Past 5.8● Present 6.5▶ Future 6.0
1 est.

Who runs Spero Therapeutics, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Mahadevia Ankit
CEO and President. First filing Nov 2017, latest Sep 3, 2025, 14 filings in all.
Officers reporting now
4
of 12 people with a filing in the last fifteen months
Directors reporting now
8
25 people on the record since 2017
Officerssales are open-market, Nov 10, 2025 to Nov 10, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Rajavelu EstherSee RemarksNov 2023Nov 10, 20265 · $400,000
Zack DebraChief Medical OfficerAug 2026Aug 6, 2026none
Keutzer TimothyChief Operating OfficerJan 2020Feb 9, 20264 · $100,000
Mahadevia AnkitCEO and PresidentNov 2017Sep 3, 2025none
Directorssales are open-market, Nov 10, 2025 to Nov 10, 2026
NameRoleFirst filingLatest filingSales, 12 months
Ho WilliamdirectorNov 2026Nov 10, 2026none
Deshpande MilinddirectorNov 2017Jun 25, 2026none
Jackson Scott ThomasdirectorApr 2020Jun 25, 2026none
Pottage John C JrdirectorSep 2018Jun 25, 2026none
Smith CynthiadirectorMar 2019Jun 25, 2026none
Thomas Frank EdirectorNov 2017Jun 25, 2026none
Tregoning KathleendirectorOct 2021Jun 25, 2026none
Vink Patrick V.J.J.directorNov 2017Jun 25, 2026none
Earlier names on the record23, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton SPRO · research, not advice